Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Apellis Pharmaceuticals Inc
APLSCurrent price
38.88 USD
+1.66 USD (+4.46%)
Last closed
37.39 USD
Company
www.apellis.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
4 496 610 304 USD
Yield for 12 month
+21.69 %
1Y
3Y
5Y
10Y
15Y
APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
74.94 USDP/E ratio
–Dividend Yield
–Current Year
+396 591 000 USD
Last Year
+75 422 000 USD
Current Quarter
+172 325 000 USD
Last Quarter
+146 377 000 USD
Current Year
+336 377 000 USD
Last Year
+69 786 000 USD
Current Quarter
+151 672 000 USD
Last Quarter
+126 465 000 USD
Key Figures APLS
1 year
3 years
5 years
10 years
EBITDA
-402 320 992 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-27.9 %
PEG Ratio
–
Return On Equity TTM
-122.94 %
Wall Street Target Price
74.94 USD
Revenue TTM
524 070 016 USD
Book Value
2.2 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
284.3 %
Dividend Yield
–
Gross Profit TTM
69 786 000 USD
Earnings per share
-3.43 USD
Diluted Eps TTM
-3.43 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-79.62 %
Dividend Analytics APLS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History APLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation APLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
15.1377
Price Sales TTM
15.7466
Enterprise Value EBITDA
-12.123
Price Book MRQ
32.0979
Financials APLS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators APLS
For 52 weeks
19.83 USD
73.8 USD
50 Day MA
40.18 USD
Shares Short Prior Month
13 899 907
200 Day MA
52.15 USD
Short Ratio
11.15
Shares Short
14 814 085
Short Percent
16.87 %
BeatStart